Conclusion
As the most prominent consumers of prescription medications, elderly patients stand to benefit the most and are also at greatest risk of toxicity from our increasingly complex, effective, and costly pharmacopoeia. When pharmacotherapy is indicated, choosing the right drug in the right dose for an elderly patient represents one of the most difficult challenges in all of medicine, but also can yield the most gratifying outcomes. Likewise, few interventions in geriatric practice are as elegant in process, and as “heroic” in outcome, as identifying and treating adverse drug effects. Thorough knowledge of some of the principles outlined here will enable the clinician to wield this powerful double-edged sword with the least possible risk and with the maximum benefit for patients.
It is much easier to write upon a disease than upon a remedy. The former is in the hands of nature and a faithful observer with an eye of tolerable judgement cannot fail to delineate a likeness. The latter will ever be subject to the whim, the inaccuracies, and the blunder of mankind. William Withering, 1741–1799
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Schmucker DL. Aging and drug disposition: an update. Pharmacol Rev. 1985;37:133–148.
Castleden CM, Volans CN, Raymond K, et al. The effect of ageing on drug absorption from the gut. Age Ageing. 1977;6:138–143.
Schwartz JB. Clinical pharmacology. In: Hazzard WR, Bierman EL, Blass JP, Ettinger WH Jr, Halter JB, eds. Principles of Geriatric Medicine and Gerontology, 3rd Ed. New York: McGraw-Hill; 1994.
Campion EW, deLabry LO, Glynn RJ. The effect of age on serum albumin in healthy males: report from the Normative Aging Study. J Gerontol. 1988;43:M18–M20.
Grandiston MK, Boudinot FD. Age-related changes in protein binding of drugs: implications for therapy. Clin Pharmacokinet. 2000;38:271–290.
MacLennan WJ, Martin P, Mason BJ. Protein intake and serum albumin levels in the elderly. Gerontology. 1977; 23:360–367.
Conti MC, Goralnik JH, Salive ME, Sarkin JD. Serum albumin level and physical disability as predictors of mortality in older persons. JAMA. 1994;272:1036–1042.
Greenblatt DJ, Sellers EM, Koch-Weser J. Importance of protein binding for the interpretation of serum or plasma drug concentrations. J Clin Pharmacol. 1982;22:259–263.
Frontera WR, Hughes VA, Lutz KJ, Evans WJ. A cross-sectional study of muscle strength and mass in 45-to 78-yr-old men and women. J Appl Physiol. 1991;71:644–650.
Thurmann PA, Hompesch BC. Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther. 1998;36:586–590.
Vestal RE. Aging and pharmacology. Cancer. 1997;80: 1302–1310.
Kinirons MT, Crome P. Clinical pharmacokinetic consid-erations in the elderly. Clin Pharmacokinet. 1997;33:302–312.
Mooney H, Roberts R, Cooksley WGE, et al. Alterations in the liver with aging. Clin Gastroenterol. 1985;14:757–771.
Vestal RE, Norris AH, Tobin JD, et al. Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking. Clin Pharmacol Ther. 1975;18:425–432.
Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology. 1999; 45:243–253.
Rowe JW, Andres R, Tobin JD, et al. The effect of age on creatinine clearance in man. J Gerontol. 1976;31:155–163.
Lindeman RD, Tobin JD, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33:278–285.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
Friedman JR, Norman DC, Yoshikawa TT. Correlation of estimated renal function parameters versus 24-hour creatinine clearance in ambulatory elderly. J Am Geriatr Soc. 1989;37:145–149.
Abernethy DR. Aging effects on drug disposition and effect. Geriatr Nephrol Urol. 1999;9:15–19.
Greenblatt DJ, Divoll M, Harmatz JS, et al. Kinetics and clinical effects of flurazepam in young and elderly insomniacs. Clin Pharmacol Ther. 1981;30:475–486.
Greenblatt DJ. Benzodiazepine hypnotics: sorting the pharmacokinetic facts. J Clin Psychiatry. 1991;52(suppl 9): 4–10.
Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA. 1989;262:3303–3307.
Greenblatt DJ, Allen MD, Shader RI. Toxicity of high-dose flurazepam in the elderly. Clin Pharmacol Ther. 1977;21: 355–361.
Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations (part I). Clin Pharmacokinet. 1991; 21:165–177.
Turnheim K. Drug dosage in the elderly. Is it rational? Drugs Aging. 1998;13:357–379.
Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI. Sensitivity to triazolam in the elderly. N Engl J Med. 1991;324:1691–1698.
Reidenberg MM, Levy M, Warner H, et al. Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clin Pharmacol Ther. 1978; 23:371–374.
Castleden CM, George CF, Marcer D, et al. Increased sensitivity to nitrazepam in old age. Br Med J. 1977;1:10–12.
Fischer M. Effect of age on pharmacokinetics and pharmacodynamics in man. Int J Clin Pharmacol Ther. 1998; 36:581–585.
Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderla: therapeutic considerations (part II). Clin Pharmacokinet. 1991;21:262–273.
O’Malley K, Stevenson IH, Ward CA, et al. Determinants of anticoagulant control in patients receiving warfarin. Br J Clin Pharmacol. 1977;4:309–314.
Shephard AMM, Hewick DS, Moreland TA. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol. 1977;4:315–320.
Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Aging and the anticoagulant response to warfarin. Ann Intern Med. 1992;116:901–904.
Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet. 1998; 35:49–64.
Greenblatt DJ, Shader RI, Harmatz JS. Implications of altered drug disposition in the elderly: studies of benzodiazepines. J Clin Pharmacol. 1989;29:866–872.
Berlinger WG, Goldberg MJ, Spector R, Chiang CK, Ghoneim M. Diphenhydramine: kinetics and psychomotor effects in elderly women. Clin Pharmacol Ther. 1982;32:387–391.
Nolan L, O’Malley K. Prescribing for the elderly. Part I: Sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc. 1988;36:142–149.
Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med. 1991;114:956–966.
Flaherty JH. Psychotherapeutic agents in older adults. Commonly prescribed and over-the-counter remedies: causes of confusion. Clin Geriatr Med. 1998;14:101–127.
Larson EB, Kukull WA, Buchner D, et al. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med. 1987;107:169–173.
Cantu TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med. 1991;114:1027–1034.
Gray SL, Lai KV, Larson EB. Drug-induced cognition disorders in the elderly: incidence, prevention, and management. Drug Saf. 1999;21:101–122.
Verhaeverbeke I, Mets T. Drug-induced orthostatic hypotension in the elderly: avoiding its onset. Drug Saf. 1997;17:105–118.
Sweet RA, Pollock BG. New atypical antipsychotics. Experience and utility in the elderly. Drugs Aging. 1998;12:115–127.
Chan YC, Pariser SF, Neufeld G. Atypical antipsychotics in older adults. Pharmacotherapy. 1999;19:811–822.
Cohen JS. Avoiding adverse reactions. Effective lowerdose drug therapies for older patients. Geriatrics. 2000;55: 54–56, 59–60, 63–64.
Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. Br Med J. 1997;315:1096–1099.
Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of thiazide diuretic therapy during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994;272:781–786.
Gurwitz JH, Kalish SC, Bohn RL, et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol. 1997;50:953–959.
Avorn J, Gurwitz JH, Bohn RL, et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA. 1995;274:1780–1782.
Monane M, Avorn J, Beers MH, Everitt DE. Anticholinergic drug use and bowel function in nursing home patients. Arch Intern Med. 1993;153:633–638.
Rochon PA, Gurwitz JH. Drug therapy. Lancet. 1995;346: 32–36.
Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987; 316:363–369.
Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Zolpiderm use and hip fractures in older people. J Am Geriatr Soc. 2001;49:1685–1690.
Herings RMC, Stricker BHC, de Boer A, Bakker A, Sturmans A. Benzodiazepines and the risk of falling leading to femur fractures. Arch Intern Med. 1995;155:1801–1807.
Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N. Use of selective serotonin-reputake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet. 1998;351:1303–1307.
Thapa PB, Gideon P, Cost TW, Milam AB, Ray WA. Antidepressants and the risk of falls among nursing home residents. N Engl J Med. 1998;339:875–882.
Thapa PB, Gideon P, Cost TW, Milam AB, Ray WA. Antidepressants and the risk of falls among nursing home residents. N Engl J Med. 1998;339:875–882.
Fifth ACCP Consensus Conference on Antithrombotic Therapy (1998): summary and recommendations. Chest 1998;114 (suppl):439S–769S.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147:1561–1564.
Feinberg WM, Blackshear J, Laupacis A, Kronmal R, Hart RG. Prevelance, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med. 1995;155:469–473.
Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–1457.
Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897–902.
Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med. 1993;118:511–520.
Kalish S, Gurwitz JH, Avorn J. Anticoagulant therapy in the elderly. Prim Cardiol. 1993;7:34–42.
Landefeld CS, Anderson PA. Guideline-based consultation to prevent anticoagulant-related bleeding. A randomized, controlled trial in a teaching hospital. Ann Intern Med. 1992;116:829–837.
Poller L, Shiach CR, MacCallum PK, et al. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet. 1998;352:1505–1509.
Gurwitz JH, Avorn J, Ross-Degnan D, Lipsitz LA. Nonsteroidal anti-inflammatory drug-associated azotemia in the very old. JAMA. 1990;264:471–475.
Bollini P, Garcia Rodriguez LA, Perez Gutthann S, Walker AM. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med. 1992;152:1289–1295.
Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med. 1991;325:87–91.
Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA. 1994: 272:1845–1850.
Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med. 2000;132:134–143.
Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med. 2000;132:134–143.
Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. Ann Intern Med. 2000;133:1–9.
Strahan GW. An overview of nursing homes and their current residents: data from the 1995 national nursing homes survey. Advance Data from Vital and Health Statistics, no. 280. Hyattsville, MD: National Center for Health Statistics; 1997.
Bernabei R, Gambassi G, Lapane K, et al. Characteristics of the SAGE database: a new resource for research on outcomes in long-term care. SAGE (Systematic Assessment of Geriatric drug use via Epidemiology) Study Group. J Gerontol Ser A Biol Sci Med Sci. 1999;54:M25–M33.
Gerety MB, Cornell JE, Plichta DT, Eimer M. Adverse events related to drugs and drug withdrawal in nursing home residents. J Am Geriatr Soc. 1993;41:1326–1332.
Gurwitz JH, Sanchez-Cross MT, Eckler MA, Matulis J. The epidemiology of adverse and unexpected events in long-term care setting. J Am Geriatr Soc. 1994;42:33–38.
Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000;109:87–94.
Rango N. Nursing home care in the United States. N Engl J Med. 1982;307:883–889.
Elon R, Paulson LG. The impact of OBRA on medical practice within nursing facilities. J Am Geriatr Soc. 1992; 40:958–963.
Ray WA, Taylor JA, Meador KG, et al. A randomized trial of a consultation service to reduce falls in nursing homes. JAMA. 1997;278:557–562.
Avorn J, Soumerai SB, Everitt DE, et al. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med. 1992;327:168–173.
Ray WA, Taylor JA, Meador KG, et al. Reducing antipsychotic drug use in nursing homes. A controlled trial of provider education. Arch Intern Med. 1993;153:713–721.
Gurwitz JH, Monette J, Rochon PA, Eckler MA, Avorn J. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med. 1997;157:978–984.
Berwick DM. Continuous improvement as an ideal in health care. N Engl J Med. 1989;320:53–56.
Leape LL. Error in medicine. JAMA. 1994;272:1851–1857.
Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events. JAMA. 1995;274:35–43.
Horton R. The uses of error. Lancet. 1999;353:422–423.
Teich JM, Merchia PR, Schmiz JL, Kuperman GJ, Spurr CD, Bates DW. Effects of computerized physician order enty on prescribing practices. Arch Intern Med. 2000;160:2741–2747.
Rothschild JM, Bates DW, Leape L. Preventable medical injuries in older patients. Arch Intern Med. 2000;160: 2717–2728.
Kohn LT, Corrigan JM, Donaldson MS, eds. To Err Is Human: Building a Safer Health System. Washington, DC: National Academy Press; 1999.
Bates DW, Leape LL, Cullen DJ, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA. 1998; 280:1311–1316.
Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Expliit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med. 1991;151:1825–1832.
Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med. 1997;157:1531–1536.
Gurwitz JH. Suboptimal medication use in the elderly. The tip of the iceberg. JAMA. 1994;272:292–296.
Gonzales R, Steiner JF, Lum A, Barrett PH Jr. Decreasing antibiotic use in ambulatory practice: impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults. JAMA. 1999;281: 1512–1519.
Gurwitz JH, Monette J, Rochon PA, Eckler MA, Avorn A. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med. 1997;157: 978–984.
Greenblatt DJ, Harmatz JS, Zinny MA, et al. Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. N Engl J Med. 1987;317:722–728.
Busto U, Sellers EM, Naranjo CA, et al. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med. 1986;315:854–859.
Danielson M, Lundback M. Withdrawal of antihypertensive drugs in mild hypertension. Acta Med Scand. 1981; 646(suppl 1):127–131.
Walma EP, Hoes AW, van Dooren C, Prins A, van der Does E. Withdrawal of long-term diuretic medication in elderly patients: a double blind randomised trial. Br Med J. 1997; 315:464–468.
Fleg JL, Gottlieb SH, Lakatta EG. Is digoxin really important in treatment of compensated heart failure? A placebo-controlled crossover study in patients with sinus rhythm. Am J Med. 1982;73:244–250.
Gheorghiade M, Beller GA. Effect of discontinuing maintenance digoxin therapy in patients with ischemic heart disease and congestive heart failure in sinus rhythm. Am J Cardiol. 1983;51:1243–1250.
Yusuf S, Garg R, Held P, Gorlin R. Need for a large randomized trial to evaluate the effects of digitalis on morbidity and mortality in congestive heart failure. Am J Cardiol. 1992;69:64G–70G.
Forman DE, Coletta D, Kenny D, et al. Clinical issues related to discontinuing digoxin therapy in elderly nursing home patients. Arch Intern Med. 1991;151:2194–2198.
Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med. 1993;329:1–7.
Rochon PA, Anderson GM, Tu JV, et al. Age and gender-relate use of low-dose drug therapy: the need to manufacture low-dose therapy and evaluate the minimum effective dose. J Am Geriatr Soc. 1999;47:954–959.
Rochon PA, Tu JV, Anderson GM, et al. Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction. Lancet. 2000;356:639–644.
Gurwitz JH, Gore JM, Goldberg RJ, et al., For the participants in the National Registry of Myocardial Infarction. Ann Intern Med. 1998;129:597–604.
Rochon PA, Fortin PR, Dear KBG, Minaker KL, Chalmers TC. Reporting of age data in clinical trials of arthritis: deficiencies and solutions. Arch Intern Med. 1993;153:243–248.
Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal antiinflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114:257–263.
Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J. 1996;312:1563–1566.
Gurwitz JH, Avorn J, Ross-Degnan D, Lipsitz LA. Non-steroidal anti-inflammatory drug-associated azotemia in the very old. JAMA. 1990;264:471–475.
Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994;272:781–786.
Schumann K. Interactions between drugs and vitamins at advanced age. Int J Vitam Nutr Res. 1999;69:173–178.
Coleman LM, Fowler LL, Williams ME. Use of unproven therapies by people with Alzheimer’s disease. J Am Geriatr Soc. 1995;43(7):747–750.
Fugh-Berman A. Herb-drug interactions. Lancet. 2000; 355:134–138.
Gold JL, Laxer DA, Dergal JM, Lanctot KL, Rochon PA. Herb-drug therapy interactions: A focus on dementia. Curr Opin Clin Nutr Metab Care. 2001;4(1):29–34.
Rochon PA, Gurwitz JG. Prescribing for seniors: neither too much nor too little. JAMA. 1999;282:113–115.
Mitchell JB. Physician visits to nursing homes. Gerontologist. 1982;22:45–48.
Gurwitz JH, Soumerai SB, Avorn J. Improving medication prescribing and utilization in the nursing home. J Am Geriatr Soc. 1990;38:542–552.
Anonymous. Conditions of participation-pharmaceutical services. Fed Reg. 1974;39:12–17.
Ray WA, Federspiel CF, Schaffner W. A study of antipsychotic drug use in nursing homes: epidemiologic evidence suggesting misuse. Am J Public Health. 1980;70:485–491.
Ingman SR, Lawron IR, Pierpaoli PG, et al. A survey of the prescribing and administration of drugs in a long-term care institution for the elderly. J Am Geriatr Soc. 1975;23: 309–316.
Beers M, Avorn J, Soumerai SB, et al. Psychoactive medication use in intermediate-care facilities. JAMA. 1988;260:3016–3020.
Buck JA. Psychotropic drug practice in nursing homes. J Am Geriatr Soc. 1988;36:409–418.
Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990;38:553–563.
Avorn J, Soumerai SB, Everitt DE, et al. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med. 1992;327:168–173.
Everitt DE, Fields DR, Soumerai SS, Avorn J. Resident behavior and staff distress in the nursing home. J Am Geriatr Soc. 1991;39:792–798.
Ray WA, Taylor JA, Meador KH, et al. Reducing antipsychotic drug use in nursing homes: a controlled trial of provider education. Arch Intern Med. 1993;153:713–721.
Svarstad BL, Mount JK. Nursing home resources and tranquilizer use among the institutionalized elderly. J Am Geriatr Soc. 1991;39:869–875.
Rich MW, Beckham V, Wittenberg C, Leven CL, Greedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1213–1214.
Tinetti ME, Baker DI, McAvay G, et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med. 1994;331: 872–873.
Elston Lafata J, Martin SA, Kaatz S, Ward RE. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med. 2000;15:31–37.
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–3264.
Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA. 1991;268:1417–1422.
Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infraction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009.
Lewis SJ, et al. Effect on pravastatin on cardiovascular events in older patients with myocardial infraction and cholesterol levels in the average range. Ann Intern Med. 1998;129:681–689.
Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reducatase inhibitor therapy in older patients with myocardial infraction. Ann Intern Med. 2000;132:780–787.
Shepherd J, et al. The design of a prospective study of pravastatin in the elderly at risk (PROSPER). Am J Cardiol. 1999;84:1192–1197.
Guideline for the Study of Drugs Likely to Be Used in the Elderly. Rockville, MD: Center for Drug Evaluation and Research, Food and Drug Administration; 1989.
Rights and permissions
Copyright information
© 2003 Springer-Verlag New York, Inc.
About this chapter
Cite this chapter
Avorn, J., Gurwitz, J.H., Rochon, P. (2003). Principles of Pharmacology. In: Geriatric Medicine. Springer, New York, NY. https://doi.org/10.1007/0-387-22621-4_7
Download citation
DOI: https://doi.org/10.1007/0-387-22621-4_7
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-95514-8
Online ISBN: 978-0-387-22621-7
eBook Packages: Springer Book Archive